Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Embla Medical hf (FRA:5IQ) reports robust sales growth and profitability, despite facing hurdles in the patient care segment and European markets.
Embla Medical hf (OSSUY) reports a 15% revenue increase and 21% net profit growth, despite challenges in EBITDA margin and gross profit.
Announcement no. 5/2026
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.